Advertisement

Topics

US FDA accepts Amgen's sBLA to expand indication for Xgeva to include MM patients

09:32 EDT 21 Jun 2017 | PharmaBiz

Amgen has announced that the US Food and Drug Administration (FDA) has accepted the Xgeva (denosumab) supplemental Biologics License Application (sBLA) that seeks to expand the currently approved

Original Article: US FDA accepts Amgen's sBLA to expand indication for Xgeva to include MM patients

NEXT ARTICLE

More From BioPortfolio on "US FDA accepts Amgen's sBLA to expand indication for Xgeva to include MM patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...